All posts by: Michael Zand

Tasmanian Devil Cancer Immunotherapy – The Scientist

Tasmanian Devil Cancer ImmunotherapyThe ScientistResearchers in Australia claim to have successfully used immunotherapy to treat devil facial tumour disease. By Bob Grant | March 13, 2017. WIKIMEDIA, KERESHScientists working to slow the spread of a dea… Continue reading

Synthetic biology companies surpassed 400 in 2016 – The Pharma Letter (registration)

Synthetic biology companies surpassed 400 in 2016The Pharma Letter (registration)The number of companies in the synthetic biology industry globally has almost doubled over a five-year period, a report shows. There were 220 companies in this space in … Continue reading

Stem Cell Therapy – Runner’s World

Runner’s World

Stem Cell Therapy Runner’s World Stem cells are immature cells that have the ability to grow into many different types of cells. In sports medicine, stem cells are harvested and then injected into an injured area, says Jonathan Finnoff, D.O., professor of physical medicine and … Has stem cell therapy helped the Boden’s poster girl say her first words? Cerebral palsy patient Holly, 11, shows …Daily Mail At 6th Annual Clinical Trial Supply New England 2017 Conference in Boston Asymmetrex Introduces A First Specific …Benzinga Celltex autologous stem cell case study published in Stem Cells and Development demonstrates favorable response in …PR Newswire (press release) EurekAlert (press release) –Yahoo Finance –Medgadget (blog) all 14 news articles »

FierceBiotech

Allergan, Editas partner on CRISPR tech in eye diseases FierceBiotech Allergan and gene editing biotech Editas have penned an upfront $90 million CRISPR research pact that will focus on ocular disorders. Under the deal, Allergan gets exclusive access and the option to license up to five of Editas’ genome-editing eye … Allergan antes up $90M in a landmark CRISPR/Cas9 collaboration with Editas on eye diseasesEndpoints News Editas and Allergan Partner on Multiple CRISPR Eye Disease ProgramsGenetic Engineering & Biotechnology News Editas, Allergan Ink $90M CRISPR-Based Eye Drug DealGenomeWeb BioPharma Dive –StreetInsider.com –EconoTimes all 30 news articles »

The FINANCIAL

Allergan and Editas Medicine Enter into Strategic R&D Alliance The FINANCIAL The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine’s unparalleled CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. Editas Medicine’s lead program is being …

Endpoints News

Allergan antes up $90M in a CRISPR/Cas9 collaboration with Editas on eye diseases Endpoints News The biotech struck a deal to partner with CRISPR/Cas9 leader Editas $EDIT on up to five programs aimed at curing eye diseases. And the package includes Editas’ lead program for Leber Congenital Amaurosis (LCA10), which is currently wrapping preclinical … Allergan (AGN), Editas Medicine (EDIT) Enter Alliance to Discover and Develop CRISPR Genome Editing Medicines …StreetInsider.com Allergan, Editas partner on CRISPR tech in eye diseasesFierceBiotech First Trial in Sight, Editas Cuts $90M Eye Drug Deal With AllerganXconomy Reuters –CNA Finance (press release) all 14 news articles »

Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing … EconoTimes The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine’s unparalleled CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. Editas Medicine’s lead program is being …

Allergan (AGN), Editas Medicine (EDIT) Enter Alliance to Discover and Develop CRISPR Genome Editing Medicines … StreetInsider.com The agreement covers early stage, first-in-class ocular programs targeting serious diseases based on Editas Medicine’s unparalleled CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. Editas Medicine’s lead program is being … and more »